AYTU BIOPHARMA INC

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

AYTU$1.79-2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

PART I - FINANCIAL INFORMATION Item 1. Financial Statements Unaudited Consolidated Balance Sheets

PART 1 - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	September 30,	June 30,
	2024	2024
ASSETS
Current assets:
Cash and cash equivalents	$20,108	$20,006
Accounts receivable, net	23,159	23,526
Inventories	11,739	12,141
Prepaid expenses and other current assets	5,732	5,097
Current assets of discontinued operations	—	1,121
Total current assets	60,738	61,891
Non-current assets:
Property and equipment, net	692	693
Operating lease right-of-use assets	1,225	829
Intangible assets, net	51,205	52,453
Other non-current assets	1,971	2,185
Non-current assets of discontinued operations	—	44
Total non-current assets	55,093	56,204
Total assets	$115,831	$118,095
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$13,513	$10,314
Accrued liabilities	33,723	38,143
Revolving credit facility	4,270	2,395
Current portion of debt	1,857	1,857
Other current liabilities	7,889	8,962
Current liabilities of discontinued operations	—	557
Total current liabilities	61,252	62,228
Non-current liabilities:
Debt, net of current portion	10,430	10,877
Derivative warrant liabilities	9,402	12,745
Other non-current liabilities	4,921	4,529
Total non-current liabilities	24,753	28,151
Commitments and contingencies (note 13)
Stockholders’ equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock, par value $.0001; 200,000,000 shares authorized; 6,149,202, and 5,972,638 shares issued and outstanding, respectively	1	1
Additional paid-in capital	348,324	347,688
Accumulated deficit	(318,499)	(319,973)
Total stockholders’ equity	29,826	27,716
Total liabilities and stockholders’ equity	$115,831	$118,095

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.